Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

- Japan now offers ELEVIDYS gene therapy to children with Duchenne muscular dystrophy aged 3 years to less than 8 years - Company is eligible to receive a $40 million milestone payment upon first commercial sale in Japan CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 24, 2026-- Sarepta Therapeutics, Inc.